EMA Authorised: mResvia (Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation) — Moderna Biotech Spain, S.L.

View source ↗

Summary

mResvia, an mRNA vaccine encoding RSV F protein in prefusion conformation, has been authorised in the EU for respiratory syncytial virus infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• mResvia (Respiratory syncytial virus mRNA vaccine (nucleoside modified))

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Infections. MAH: Moderna Biotech Spain, S.L.. Decision date: 27/04/2026